

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)

The Derbyshire commissioning guidelines for the treatment of severe psoriasis in adults

This algorithm is a tool to aid the implementation of NICE guidance on biologic drugs for the treatment of psoriasis. It includes all of the biologic drugs approved by NICE for treatment and local variations for the commissioning algorithm.

Severe Psoriasis: **PASI ≥ 10 and DLQI > 10 and failed previous systemic therapies or these treatments are CI or not tolerated** (e.g. ciclosporin, methotrexate or PUVA (psoralen and long-wave ultraviolet radiation))

If more than 1 treatment is suitable, the least expensive should be chosen. Choices are listed in most cost-effective order. **(IV and SC preparations)**

First line cost-effective treatment option:

- **Adalimumab biosimilar (TNFi) (TA146)**

Alternative treatment options if first line biologic is clinically inappropriate:

- Tildrakizumab (IL23) (TA575) or
- Guselkumab (IL23) (TA521) or
- Bimekizumab (IL17A & 17F & 17AF) (TA723) or
- Risankizumab (IL23) (TA596) or
- Etanercept biosimilar (TNFi) (TA103) or
- Ixekizumab (IL17A) (TA442) or
- Brodalumab (IL17RA) (TA511) or
- Secukinumab (IL17A) (TA350) or
- Certolizumab (TNFi) (TA574) or
- Ustekinumab (IL12 & IL23) (TA180)

Or

- Infliximab biosimilar (TNFi) (TA134) (if disease is **very severe** as defined by PASI ≥ 20 and DLQI > 18)

(Oral preparations)

Choices are listed in most cost-effective order

- Dimethyl Fumarate (NRF2) (TA475) or
- Apremilast (PDE4) (TA419) or
- Deucravacitinib (TYK2) (TA907)

Maintain same treatment and monitor patient (See adequate response time in appendix 2)

Yes – consider alternative biologic agent – (local agreement)

Has the biologic been withdrawn because of an adverse effect?

No

If no adequate response at specified time (see appendix 2) - the patient is a **primary non-responder or secondary non-responder** (initially responds, but subsequently loses response), proceed as per local guidance below:

Previous drug treatment with an anti-TNFi biologic:

- Adalimumab biosimilar
- Infliximab biosimilar (very severe psoriasis)
- Etanercept biosimilar
- Certolizumab

Second drug option:

- Tildrakizumab
- Guselkumab
- Bimekizumab
- Risankizumab
- Ixekizumab
- Brodalumab
- Secukinumab
- Ustekinumab

Previous drug treatment with an interleukin mediated biologic:

- Tildrakizumab
- Guselkumab
- Bimekizumab
- Risankizumab
- Ixekizumab
- Brodalumab
- Secukinumab
- Ustekinumab

Second drug option:

- Adalimumab biosimilar
- Etanercept biosimilar
- Certolizumab
- Infliximab biosimilar (very severe psoriasis)

Adequate response defined as:

*a 75% reduction in the PASI score (PASI 75) from when treatment started

or

a 50% reduction in the PASI score (PASI 50) and a 5-point reduction in the DLQI score from when treatment started.

Local variation to NICE

NICE approved treatment

The ICB will only commission 2 treatment options (1 switch) per patient. JAPC recognises the RMOG statement. Further sequential use outside of the commissioning algorithm should be undertaken after advice via MDT in-line with Trust processes but is limited by clinical appropriateness and safety.

In exceptional circumstances some patients may not show adequate response to a second biologic, **and** the psoriasis may have worsened, **and** there may be a risk of readmission; under these circumstances it may be appropriate to request the use of a third biologic through from a tertiary centre (See appendix 1 for further details)

Appendix 1

Use of third biologic – through a tertiary centre

For patients who have not had an adequate response to a second biologic and the psoriasis has worsened (PASI>15 and DLQI>15) and there is a risk of readmission, use of a third biologics can be considered if

1. Approved by an MDT at a tertiary centre
2. The biologic prescribed is of a different mode of action to the previously tried therapies
3. Request is submitted to the ICB through Blueteq

Appendix 2

Biologic	Type	Route	Dose	Adequate response (weeks)	Further information
Adalimumab biosimilar (SC)	Recombinant human monoclonal antibody that binds specifically to tumour necrosis factor alpha (TNF- α).	SC	Initial 80mg dose, followed by 40mg given every other week starting 1 week after the initial dose	16	Ideal first line for patients with associated psoriatic arthritis
Apremilast (Oral)	Apremilast is an inhibitor of phosphodiesterase 4 (PDE4)	Oral	30mg taken orally twice daily, approximately 12 hours apart (morning and evening)	12	See dose titration below
Bimekizumab (SC)	Humanised IgG1 monoclonal antibody that selectively inhibits IL-17F and IL17A, 17AF	SC	320mg (2x160mg) by SC injection at week 0 - 320mg week 4 - 320mg week 8 - 320mg week 12 - 320mg week 16 - 320mg and thereafter every 8 weeks	16	Patients with a body weight of 120kg or more who did not have complete skin clearance at week 16 may improve further by increasing their dosage to 320 mg every 4 weeks.
Brodalumab (SC)	Recombinant fully human monoclonal immunoglobulin IgG2 antibody that binds with high affinity to human IL-17RA and blocks the biological activities of the pro-inflammatory cytokines IL-17A, IL-17F, IL-17A/F heterodimer and IL-25.	SC	210mg at weeks 0, 1 and 2, followed by 210mg every 2 weeks	12	Useful second line agent in patients who fail an initial biological agent or for patients at high risk of demyelinating disease or TB. Useful for patients requiring high level of clinical response. Suicidal ideation and behaviour have been reported in patients treated with brodalumab. The risk and benefit of treatment with brodalumab should be carefully weighed for patients with a history of depression and/or suicidal ideation or behaviour, or for patients who develop such symptoms. See SPC .
Certolizumab (SC)	Certolizumab binds specifically to tumour necrosis factor alpha (TNF- α).	SC	Loading dosage: 400mg (given as 2 x200mg each) at weeks 0, 2 and 4. Maintenance dosage: 200mg every 2 weeks. 400 mg every 2 weeks can be considered when there is an insufficient response.	16	Studies have shown there is no to minimal placental transfer of Certolizumab from mothers to infants. Certolizumab may be a useful option for patients willing to be become pregnant.
Deucravacitinib (Oral)	Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor	Oral	6mg orally once daily	24	Consider stopping deucravacitinib between 16 weeks and 24 weeks if there has not been at least a 50% reduction in the PASI score (PASI 50) from when treatment started
Etanercept	Recombinant human tumour necrosis factor (TNF) receptor	SC	25mg twice weekly. Alternatively	12	NA

biosimilar (SC)	fusion protein that inhibits the activity of TNF		50mg twice weekly may be used for up to 12 weeks followed, if necessary, by a dose of 25mg twice weekly		
Guselkumab (SC)	Guselkumab is a human IgG1 λ monoclonal antibody (mAb) that binds selectively to the interleukin 23 (IL-23) protein with high specificity and affinity.	SC	100mg by at weeks 0 and 4, followed by a 100mg maintenance dose every 8 weeks.	16	NA
Infliximab biosimilar** (IV/SC)	Chimeric human-murine IgG1 monoclonal antibody	IV and SC	<u>IV dose:</u> 5mg/kg at week 0,2,6, thereafter every 8 weeks <u>SC dose:</u> Week 0 and 2 – IV 5mg/kg Week 6 – 120mg SC every 2 weeks	10	Reserved for people with severe disease as per the NICE TA. PASI of 20 or more and DLQI of more than 18
Ixekizumab (SC)	Antibody that inhibits IL-17A (interleukin-17A, a pro-inflammatory cytokine).	SC	160mg at week 0, followed by 80mg every 2 weeks until week 12. After week 12, 80mg every 4 weeks	12	Useful for patients at high risk of demyelinating disease or TB. Useful for patients requiring high level of clinical response
Risankizumab (SC)	Humanised IgG1 monoclonal antibody that binds to and neutralises the p19 subunit of interleukin-23	SC	150mg at weeks 0 and 4 and every 12 weeks thereafter.	16	NA
Secukinumab (SC)	High-affinity, fully human Monoclonal antibody that binds to and neutralises interleukin-17A.	SC	300mg at weeks 0, 1, 2 & 3, followed by monthly maintenance dosing starting at week 4	12	Useful for patients at high risk of demyelinating disease or TB. Useful for patients requiring high level of clinical response
Tildrakizumab (SC)	Humanized IgG1/k monoclonal antibody that specifically binds to the p19 protein subunit of the interleukin-23 (IL-23) cytokine without binding to IL-12 and inhibits its interaction with the IL-23 receptor.	SC	100mg at weeks 0 and 4 and every 12 weeks thereafter. In patients with certain characteristics (for example, high disease burden, body weight of 90kg or more), a 200mg dose may provide greater efficacy.	28	NA
Ustekinumab (SC)	Fully human monoclonal antibody that targets interleukin-12 (IL-12) and IL-23	SC	Weight \leq 100kg - 45mg for, Weight >100kg – 90mg Administered at week 0 followed by another dose at week 4, and then a further dose every 12 weeks	16	Ustekinumab has better drug survival rates and a now well-established safety record. BAD advises as a potential first line agent in absence of psoriatic arthritis.

Appendix 3

Dose titration for Dimethyl Fumarate

To improve tolerability, it is recommended to begin treatment with a low initial dose with subsequent gradual increases. The maximum daily dose allowed is 720 mg (3 x 2 tablets of dimethyl fumarate 120 mg).

Week	Number of tablets			Total daily dose (mg) of dimethyl fumarate
	Morning	Midday	Evening	
Dimethyl fumarate 30 mg				
1	0	0	1	30
2	1	0	1	60
3	1	1	1	90
Dimethyl fumarate 120 mg				
4	0	0	1	120
5	1	0	1	240
6	1	1	1	360
7	1	1	2	480
8	2	1	2	600
9+	2	2	2	720

Dose titration for apremilast

- Day 1 - 10mg am
- Day 2 - 10mg am & pm
- Day 3 - 10mg am, 20mg pm
- Day 4 - 20mg am & pm
- Day 5 - 20mg am & 30mg pm
- Day 6 and thereafter - 30mg am & pm

NB: reduce dose 30mg od in severe renal impairment (CrCl <30ml/min, estimated using Cockcroft-Gault equation)

MHRA warning - apremilast

[MHRA](#), Jan 2017, have issued a warning regarding risk of suicidal thoughts and behavior associated with apremilast use.